» Articles » PMID: 36059526

Neuroimaging and Clinicopathological Differences Between Tumefactive Demyelinating Lesions and Sentinel Lesions of Primary Central Nervous System Lymphoma

Overview
Journal Front Immunol
Date 2022 Sep 5
PMID 36059526
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: It is still a challenge to distinguish sentinel lesions of primary central nervous system lymphoma (PCNSL) from atypical tumefactive demyelinating lesions (TDLs) in clinical practice. We aimed to investigate potential differences of clinical features, neuroimaging findings and pathological characteristics between PCNSL and TDLs, improving early accurate diagnosis.

Methods: It was a retrospective study involving 116 patients with TDLs and 150 patients with PCNSLs. All cases were pathologically confirmed. Clinical features, neuroimaging findings and pathological characteristics between two groups were analyzed.

Results: The onset age was 37 ± 14 years in TDLs and 58 ± 13 years in PCNSL(p=0.000). Main onset symptom was headache in TDLs, while cognitive impairment was frequently noted in PCNSL. CT brain scan image showed hypodense lesions in most cases of TDL (110/116, 94.8%), while approximately 80% patients (120/150) with PCNSL had hyperdense lesions. Furthermore, we found that the presence of Creutzfeldt-Peters cells (might be misdiagnosed as tumor cells) may serve as an important feature in TDLs.

Conclusions: Onset age of patients with TDLs was younger than PCNSL. Neuroimaging features on brain CT scan might provide clues to make a differential diagnosis. Pathological features of PCNSL with sentinel lesions or following steroids therapy might mimic TDLs. Dynamic neuroimaging pathological and follow-up information were essential for an accurate diagnosis.

Citing Articles

Case report: From misdiagnosis to timely detection: a clinical and imaging guide to neurological presentations of diffuse large B-cell lymphoma-insights from six cases.

Yang C, Gong Z, Wang T, Yuan H, Na W, Xie W Front Oncol. 2025; 15:1410953.

PMID: 39995838 PMC: 11847832. DOI: 10.3389/fonc.2025.1410953.


Diagnostic uncertainty of steroid-modified Marburg's variant of multiple sclerosis even at autopsy: A case suggesting lymphoma and related myelin loss.

Hanazono A, Yasuda K, Shimada H, Takahashi Y, Funasaka H, Sanpei Y eNeurologicalSci. 2024; 36:100515.

PMID: 39108350 PMC: 11300897. DOI: 10.1016/j.ensci.2024.100515.

References
1.
Lebrun C . Radiologically isolated syndrome should be treated with disease-modifying therapy - Commentary. Mult Scler. 2017; 23(14):1821-1823. DOI: 10.1177/1352458517727149. View

2.
Bajagain M, Oyoshi T, Hanada T, Higa N, Hiraki T, Kamimura K . Histopathological variation in the demyelinating sentinel lesion of primary central nervous system lymphoma. Surg Neurol Int. 2020; 11:342. PMC: 7655992. DOI: 10.25259/SNI_531_2020. View

3.
Ekmekci O, Eraslan C . Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome. Case Rep Neurol Med. 2019; 2018:8409247. PMC: 6304209. DOI: 10.1155/2018/8409247. View

4.
Chiavazza C, Pellerino A, Ferrio F, Cistaro A, Soffietti R, Ruda R . Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring. Biomed Res Int. 2018; 2018:3606970. PMC: 6033255. DOI: 10.1155/2018/3606970. View

5.
Sanchez P, Chan F, Hardy T . Tumefactive demyelination: updated perspectives on diagnosis and management. Expert Rev Neurother. 2021; 21(9):1005-1017. DOI: 10.1080/14737175.2021.1971077. View